Financial News

IMV Announces Annual and Special Meeting of Shareholders Voting Results

Products You May Like

Article content material

DARTMOUTH, Nova Scotia — IMV Inc. (“IMV” or the “Firm”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical firm, right now introduced the voting outcomes from its annual and particular assembly of shareholders held on June 18, 2021 (the “Assembly”).

Based mostly on the votes obtained, all resolutions had been accepted together with the election of administrators, for whom particulars of the votes are as follows:

Title of nominee

Votes forged

% of votes
forged FOR

Votes Withheld

% of votes Withheld

Andrew Sheldon





Michael Bailey





Julia P. Gregory





Michael Kalos





Kyle Kuvalanka





Frederic Ors





Shermaine Tilley





Markus Warmuth





Shareholders authorised the appointment of PricewaterhouseCoopers, LLP, Chartered Skilled Accountants, as impartial auditor for the Firm for the following 12 months and that the board of administrators of the Firm be approved to repair its remuneration.

As well as, all amendments to the inventory possibility plan of the Company to transform it from a “mounted” plan to a “rolling” plan as described within the administration info round dated Might 11, 2021 (the “Round”) had been authorised by the shareholders.

Article content material

Please consult with the Round accessible on SEDAR at for extra info on the enterprise transacted on the Assembly. A report on voting outcomes may even be filed on SEDAR.

IMV Ahead-Wanting Statements

This press launch comprises forward-looking info underneath relevant securities legislation. All info that addresses actions or developments that we anticipate to happen sooner or later is forward-looking info. Ahead-looking statements are based mostly on the estimates and opinions of administration on the date the statements are made. Within the press launch, such forward-looking statements embody, however aren’t restricted to, statements concerning the FDA probably granting accelerated regulatory approval of maveropepimut-S and the timing of anticipated outcomes from different maveropepimut-S’s research with different tumor varieties. Nevertheless, they shouldn’t be considered a illustration that any of the plans might be achieved. Precise outcomes could differ materially from these set forth on this press launch as a result of dangers affecting the Company, together with entry to capital, the profitable design and completion of scientific trials and the receipt and well timed receipt of all regulatory approvals. IMV Inc. assumes no duty to replace forward-looking statements on this press launch besides as required by legislation. These forward-looking statements contain identified and unknown dangers and uncertainties and people dangers and uncertainties embody, however aren’t restricted to, our capacity to entry capital, the profitable and well timed completion of scientific trials and research, the receipt of all regulatory approvals and different dangers detailed now and again in our ongoing quarterly filings and annual info kind Traders are cautioned to not depend on these forward-looking statements and are inspired to learn IMV’s steady disclosure paperwork, together with its present annual info kind, in addition to its audited annual consolidated monetary statements which can be found on SEDAR at and on EDGAR at

About IMV

IMV Inc. is a scientific stage biopharmaceutical firm devoted to creating immunotherapy more practical, extra broadly relevant, and extra extensively accessible to individuals dealing with most cancers and different severe illnesses. IMV is pioneering a brand new class of most cancers immunotherapies and vaccines towards infectious illnesses based mostly on the Firm’s proprietary drug supply platform, DPX. This patented know-how leverages a novel mechanism of motion that allows the programming of immune cells in vivo, that are aimed toward producing highly effective new artificial therapeutic capabilities. IMV’s lead candidate, maveropepimut-S, is a T cell-activating immunotherapy that mixes the utility of the platform with a goal: survivin. IMV is at present assessing maveropepimut-S as a monotherapy in superior ovarian most cancers, in addition to a mixture remedy in a number of scientific research with Merck. Go to and join with us on Twitter and LinkedIn.

View supply model on


Investor Relations

Marc Jasmin, Senior Director, Investor Relations, IMV
O: (902) 492-1819, ext: 1042
M: (514) 617-9481 E:

Irina Koffler, Managing Director, LifeSci Advisors
O: (646) 970-4681
M: (917) 734-7387


Delphine Davan, Senior Director of Communications, IMV
M: (514) 968-1046

Products You May Like

Articles You May Like

24-Hour Flash Deal: Save $529 on an HP Touch Intel Pentium Laptop
Kate Winslet Isn’t Sure Mare of Easttown Season 2 Will Happen
Sam Smith’s Tattoos & Their Meaning: Everything To Know About Their Ink
Master P Tries To Make Peace With Son Romeo After Social Media Feud: ‘My Door Is Always Open’
Wednesday’s Jenna Ortega Debuts Edgy New Look